Wearable Injectors Market

Amgen (US), Medtronic (Ireland), Insulet Corporation (US) and United Therapeutics Corporation (US) are leading players in Wearable Injectors Market

The global wearable injectors market is projected to reach USD 9.41 billion by 2023 from an estimated USD 5.57 billion in 2018, at a CAGR of 11.1%. The wearable injectors market is rapidly emerging with many regional as well as international companies. In 2017, Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutics Corporation (US), and Valeritas (US) together held a share of approximately 90–95% of the total wearable injectors market. Ypsomed (Switzerland), Becton, Dickinson and Company (US), Enable Injections (US), Sensile Medical (Switzerland), and Bespak (UK) were the top OEM companies in the global wearable injectors market.

Amgen (US) dominated the wearable injectors market for immune-oncology in 2017. The company offers wearable injector devices for the treatment of neutropenia in cancer patients. The company manufactures and distributes its products in North America, Europe, and Asia. The company primarily focuses on expanding its geographic reach to maintain its leadership position in the market. Over the last five years, the company has expanded its geographic reach from 50 countries to approximately 100 countries. In the US, the company markets its products primarily to wholesalers and distributors. The company markets certain products directly to consumers through several direct-to-consumer channels. Outside the US, the company markets its products to healthcare providers and pharmaceutical wholesalers & distributors. The company strategically focuses on strengthening its position in the wearable injectors market through collaborations and agreements. For instance, in 2018, the company collaborated with Simcere (China) to co-develop and commercialize biosimilars in China. In 2016, the company signed an agreement with Humana (US) for the development and research of medicines for cardiovascular diseases, osteoporosis, neurologic disorders, inflammatory diseases, and cancer, among others.

To know about the assumptions considered for the study download the pdf brochure

Medtronic (Ireland) offers wearable injectors for the treatment of diabetes under the brand name Minimed. The company sells its products through a direct sales force in the US and a combination of direct sales representatives and independent distributors outside the US. The company serves hospitals, clinics, third-party healthcare providers, distributors, and institutions in the Asia Pacific, Europe, the Americas, and the Middle East & Africa. In order to strengthen its position in the market, the company significantly invests in R&D activities. In 2017, the company invested USD 2.22 billion in R&D activities.

Insulet Corporation (US) offers the Omnipod wearable device for the treatment of insulin-dependent diabetics. The company focuses on agreements and partnerships to strengthen its position in the market. For instance, in 2018, the company signed a development agreement with Eli Lilly and Company to develop a wearable device for Eli Lilly’s Humalog 200 units/mL KwikPen. The company focuses on R&D investments for the development of technologically advanced products. In 2017, the company invested USD 74.5 million in R&D activities.

United Therapeutics Corporation (US) offers treprostinil injection (REMODULIN) with a wearable CADD-MS 3 pump system for the treatment of pulmonary arterial hypertension (PAH). The wearable REMODULIN pump is commercialized in the US and in the 24 member countries of the European Economic Area (EEA). This wearable pump is also approved in Canada, China, Israel, Japan, Argentina, Brazil, Chile, Mexico, Peru, Saudi Arabia, South Korea, Taiwan, and Venezuela.

Related Reports:

Wearable Injectors Market by Type (On-Body and Off-Body injectors (Infusion Pump Devices)), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases, Parkinson's disease, Thalassemia, Primary Immunodeficiency Disease) - Global Forecast to 2023

Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Report Code
MD 6659
RI Published ON
Choose License Type
Request Customization
Speak to Analyst
Speak to Analyst
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
  • What are the Known and Unknown Adjacencies Impacting the Wearable Injectors Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
©2021 MarketsandMarkets Research Private Ltd. All rights reserved